New York, New York–(Newsfile Corp. – August 12, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ:Read More
You might also be interested in reading Cadence targets 13% revenue growth and 16% EPS growth for 2025 amid strong AI demand and expanded product portfolio.
